# New tools for the new bug *Candida auris*

Alexander Lorenz[a,*] and Nicolas Papon[b]

Author affiliations:

[a]Institute of Medical Sciences (IMS), University of Aberdeen, Aberdeen, UK

[b]Univ Angers, Univ Brest, GEIHP, SFR ICAT, F-49000 Angers, France

*Correspondence should be addressed to:

Alexander Lorenz

Institute of Medical Sciences (IMS)

University of Aberdeen

Foresterhill

Aberdeen AB25 2ZD

United Kingdom

Phone: +44 1224 437323

E-mail: a.lorenz@abdn.ac.uk

**ORCIDs:** 0000-0003-1925-3713 (AL), 0000-0001-6265-7321 (NP)

**Twitter:** @LorenzLab (AL), @NicolasPapon49 (NP)

25 ABSTRACT

26 *Candida auris* is a recently emerged yeast pathogen of humans causing severe hospital-acquired
27 systemic infections. It is of the utmost importance to understand the genetic and cellular basis of its
28 virulence and pathogenicity. In a recent study, Santana & O'Meara generated forward and reverse
29 genetic tools to manipulate *C. auris*.

30

31 Key words: *Candida auris*, genetic manipulation, cellular morphogenesis

The yeast *Candida auris* was recognized as a novel human pathogen in 2009 and has turned into a major healthcare problem causing systemic infections in patients with pre-existing health conditions [1]. *C. auris* strains can be grouped into four (possibly five) geographically isolated taxonomical groups (clades); strains from different clades differ considerably from each other, genetically and phenotypically [1,2]. Research on *C. auris* in the past decade elucidated aspects of its biology, but we are far away from a comprehensive understanding of its life cycle [2]. A detailed understanding of clinically relevant traits of *C. auris*, such as virulence and antimicrobial resistance, is of particular interest, as this would enable development of new treatments which are needed in clinics to tackle this novel pathogen. Elucidation of the molecular mechanisms underpinning such clinically relevant traits in *C. auris* would require genetic tools that enable the manipulation of its genome. Early efforts have resulted in the establishment of protocols to generate gene deletions and conditional knock-downs via homology-directed repair, and to perform gene editing using CRISPR-Cas9 as an RNA-protein complex [3–5]. Although workable, these approaches have proved laborious and/or technically cumbersome. In this respect, a recent study by Santana & O'Meara [6] has established two novel genetic tools for *C. auris* research: (I) a forward genetic screen assay employing *Agrobacterium*-mediated transformation (AtMT) (Figure 1A), and (II) a DNA-based CRISPR-Cas9 system which is transiently expressed in *C. auris* and facilitates reverse genetic approaches (Figure 1B).

As a proof-of-principle, the AtMT system was used to screen for mutant yeast with an altered colony morphology (Figure 1C) [6]. The genes affected by the insertional mutagenesis of the *Agrobacterium tumefaciens* T-DNA were identified using a whole-genome sequencing approach. These morphogenetic mutants turned out to also affect cellular behaviour indicating that altered colony morphology is a good predictor of changed cellular behaviour. A set of mutants exhibited a cellular aggregation phenotype [6], a trait which previously has also been observed in some clinical *C. auris*

isolates and been associated with differences in virulence [7]. A further single mutant displaying constitutive cellular filamentation was also identified [6]; in some fungi, this cellular phenotype is associated with invasive disease. However, in *C. auris*, this has only been described as a response to genotoxic, temperature, and high-salt stress [3,4]. To verify the causative nature of these mutants isolated in the forward genetic screen, Santana & O'Meara then generated full deletions of the affected genes using a DNA-based CRISPR-Cas9 approach inspired by a similar tool developed for *Candida albicans* (Figure 1C) [6,8]. Relying solely on homology-directed, targeted integration for genetic manipulation of *C. auris* results in rather low success rates [3,6]. The frequencies of correct targeting are significantly improved by ~3- to 12-fold when CRISPR-Cas9 is applied. The main strength of the work by Santana & O'Meara is that they explore these genetic tools in *C. auris* strains belonging to the four main clades [6], demonstrating that their strategies are applicable to representatives of the whole species. Intriguingly, in terms of correct targeting efficiency, there seem to be substantial differences between strains from different clades; both with and without the support of CRISPR-Cas9 [6].

The genes of two of the constitutively aggregating mutants from AtMT were identified as orthologs of *Saccharomyces cerevisiae ACE2* and *TAO3* (Figure 1C) [6]. Indeed, the full deletion mutants *ace2*Δ and *tao3*Δ recapitulated the aggregation phenotype of the insertion mutants generated with the AtMT system [6]. Using the CRISPR-Cas9 tool again the wild-type condition was restored, which conclusively demonstrated that these genes are determinants of cellular and colony morphology in *C. auris*. In *S. cerevisiae* Tao3 is a regulator of Ace2 in the RAM (Regulation of *ACE2* morphogenesis) pathway which mediates septum degradation during cell division. Indeed, this function of the RAM pathway is conserved, as mutation of *ACE2* or its upstream regulators, such as *TAO3*, causes a cellular aggregation phenotype in *S. cerevisiae*, *C. albicans*, and *C. auris* [6]. Santana & O'Meara then also demonstrate that in both *ace2*Δ and *tao3*Δ mutants a key enzyme involved in degradation of the

80 septum during cell division, the chitinase Cts1, is downregulated [6]. On a mechanistic level, this
81 would explain the cell aggregation phenotype of *C. auris* that is likely caused by an inability to
82 efficiently degrade the septum thus causing the daughter cells to stick together. Further tests
83 indicated that the *ace2*Δ mutant, in contrast to the *tao3*Δ mutant, did modestly affect virulence.
84 Whereas the *tao3*Δ mutant exhibited increased resistance to some antifungal drugs, while the *ace2*Δ
85 mutant displayed wild-type levels of antifungal drug susceptibility [6].

86 The mutant isolated from the AtMT screen with a constitutive cellular filamentation and aggregation
87 phenotype affected the ortholog of the *ELM1* gene; again this was confirmed by independently
88 generated deletion mutants and by subsequently restoring the wild-type condition using the CRISPR-
89 Cas9 tool (Figure 1C) [6]. In *S. cerevisiae*, the Elm1 kinase regulates morphogenetic differentiation
90 and cell division; this seems to be conserved in *C. auris* and also in *Candida glabrata* [6]. Intriguingly
91 and in stark contrast to the *ace2*Δ and *tao3*Δ mutants, expression of the Cts1 chitinase is upregulated
92 in the *elm1*Δ mutant [6], indicating that the aggregation phenotype of the latter might have different
93 causes than of the former.

94 The establishment of *Agrobacterium*-mediated transformation (AtMT) and DNA-based CRISPR-Cas9
95 in *C. auris* by Santana & O'Meara [6] is a great technical advance. Another forward genetics tool,
96 transposon mutagenesis, has recently been adapted for *C. auris* [9], adding to the growing molecular
97 biology tool box to study this yeast. As a proof-of-principle, Santana & O'Meara screened for and
98 characterized mutants with altered colony and cellular morphology [6]. The screens were by no
99 means exhaustive, and further studies will be needed to follow up on these initial insights. Together
100 with new infection models [10], this will be immensely useful to the budding *C. auris* research
101 community and to the wider medical mycology field, because this is an essential prerequisite for

expediting therapeutic development and thus for improving management of life threatening *C. auris* infections in the near future.

## References


1 Rhodes, J. and Fisher, M.C. (2019) Global epidemiology of emerging *Candida auris*. *Curr. Opin. Microbiol.* 52, 84–89

2 Bravo Ruiz, G. and Lorenz, A. (2021) What do we know about the biology of the emerging fungal pathogen of humans *Candida auris*? *Microbiol. Res.* 242, 126621

3 Bravo Ruiz, G. *et al.* (2020) Pseudohyphal growth of the emerging pathogen *Candida auris* is triggered by genotoxic stress through the S phase checkpoint. *mSphere* 5, e00151-20

4 Kim, S.H. *et al.* (2019) Genetic analysis of *Candida auris* implicates Hsp90 in morphogenesis and azole tolerance and Cdr1 in azole resistance. *mBio* 10, e02529-18

5 Grahl, N. *et al.* (2017) Use of RNA-Protein complexes for genome editing in non-*albicans* *Candida* species. *mSphere* 2, e00218-17

6 Santana, D.J. and O'Meara, T.R. (2021) Forward and reverse genetic dissection of morphogenesis identifies filament-competent *Candida auris* strains. *Nat. Commun.* 12, 7197

7 Borman, A.M. *et al.* (2016) Comparative pathogenicity of United Kingdom isolates of the emerging pathogen *Candida auris* and other key pathogenic *Candida* species. *mSphere* 1, e00189-16

8 Ng, H. and Dean, N. (2017) Dramatic improvement of CRISPR/Cas9 editing in *Candida albicans* by increased single guide RNA expression. *mSphere* 2, e00385-16

9 Gao, J. *et al.* (2021) LncRNA DINOR is a virulence factor and global regulator of stress responses in *Candida auris*. *Nat. Microbiol.* 6, 842–851

10 Huang, X. *et al.* (2021) Murine model of colonization with fungal pathogen *Candida auris* to explore skin tropism, host risk factors and therapeutic strategies. *Cell Host Microbe* 29, 210-221.e6

## Figure Legend

**Figure 1. New forward and reverse genetic tools for *C. auris*.** **(A) Development of a forward genetic screen assay employing *Agrobacterium*-mediated transformation (AtMT).** The native Ti plasmid from *A. tumefaciens* was modified for transferring nourseothricin resistance (*NAT1* selectable marker) to *C. auris* after co-culture of *A. tumefaciens* and *C. auris*. Note, that in such an approach a single copy of the T-DNA, delimited by both right and left borders (LB and RB), is integrated randomly into the genome of the recipient *C. auris* strain. **(B) CRISPR-Cas9 expression system for targeted transformation of *C. auris*.** The upper panel depicts structures of the Cas9 and sgRNA expression cassettes. *CAS9* is driven by the *C. auris* enolase gene (*ENO1*) promoter and followed by the cytochrome c gene (*CYC1*) terminator. The sgRNA cassette is regulated by the *C. auris ADH1* (alcohol dehydrogenase gene) promoter and the terminator of the *Ashbya gossypii* translational elongation factor 2 gene (*AgTEF2*), and contains *C. auris* tRNA-Ala, 20-bp gRNA sequence, tracrRNA sequence, and hepatitis delta virus (HDV) ribozyme sequence. The lower panel shows the cassette specifically designed for targeted integration in *C. auris* by using homologous recombination. The cassette combines a red fluorescent protein (*RFP*) gene as a marker for correct targeted integration (this is not an essential part of the deletion cassette), *ADH1* terminator, *AgTEF2* promoter, *NAT1* nourseothricin resistance gene, and *AgTEF2* terminator. To achieve correct integration into the

146 genome, this cassette must be flanked by approximately 500 bp 5' and 3' UTR of your favourite *C.*
147 *auris* gene (*YFG*) to be disrupted. The right lower panel shows the molecular construct developed for
148 functional complementation of deleted genes. The cassette combines *ADH1* terminator, *AgTEF2*
149 promoter, a G418 resistance marker (*NEO*) (novel to *C. auris*), and *AgTEF2* terminator. To drive
150 correct integration into the genome, this cassette must contain at the 5' extremity 500 bp of the
151 5'UTR plus the complete coding sequence of *YFG* and at the 3' end approximately 500 bp 3' UTR of
152 *YFG* to be reconstituted. **(C) Identification of *C. auris* morphogenesis associated genes.** AtMT first led
153 to the isolation of some morphogenetic mutants. For instance, three of these mutants were found to
154 bear T-DNA integration in the *ACE2*, *TAO3* and *ELM1* loci, respectively. The involvement of these
155 genes in *C. auris* morphogenesis was confirmed by independently disrupting them in *C. auris* strains
156 from different clades, and then reintegrating functional *ACE2*, *TAO3* and *ELM1* genes for
157 complementation.


A
Ti plasmid
LB
NAT1
RB
Candida auris
Random insertion
Agrobacterium tumefaciens
Ti
T-DNA
B
Cas9 cassette
P CaENO1
CaCas9
T CYC1
sgRNA cassette
P CaADH1
tRNA-Ala gRNA tracrRNA
HDV
T AgTEF2
Deletion
RFP
T ADH1
P AgTEF2
NAT1
T AgTEF2
P YFG
YFG
T YFG
Complementation
YFG
NEO
C
Colony
Cells
Mutation
WT
AtMT
→ CauACE2
→ CauTAO3
→ CauELM1
Genotype
DELETIONS
Cauace2Δ
Cautao3Δ
Cauelm1Δ
Deletions
COMPLEMEN-TATION
Cauace2Δ + CauACE2
Cautao3Δ + CauTAO3
Cauelm1Δ + CauELM1